[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Obstetrics & Gynecology Hospital of Fudan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":478},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,44,67,100,121,147,170,193,220,240,264,284,305,324,345,365,390,411,431,456],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644766","phase-2-iparomlimab-and-tuvonralimab-plus-chemotherapy-as-neoadjuvant-therapy-for-ovarian-cancerphase-ii-100644766",false,"NCT07673835","Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II）","Efficacy of Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer: A Single-Arm, Single-Center Phase II Trial","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma, FIGO 2014 stage III-IV disease;\n2. Female patients aged 18 to 75 years;\n3. Willing and able to provide written informed consent and comply with study visits and protocol-specified procedures;\n4. Candidates for cytoreductive surgery (debulking surgery);\n5. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n7. Estimated life expectancy of at least 6 months;\n8. Women of childbearing potential must agree to use effective contraception during the study period, and a negative serum or urine pregnancy test is required prior to enrollment;\n9. Adequate organ function.\n\nExclusion Criteria:\n\n1. Histological subtypes other than epithelial ovarian carcinoma, including mucinous carcinoma and clear cell carcinoma.\n2. Pregnant women or patients whose most recent pregnancy was terminated within 2 weeks prior to screening.\n3. Clinically significant hydronephrosis not amenable to stenting or nephrostomy, or presence of CNS metastases or carcinomatous meningitis.\n4. History of other malignancies within 3 years, except for adequately treated curable cancers (e.g., skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, or carcinoma in situ of the breast).\n5. Prior treatment with immune checkpoint inhibitors or other immunomodulatory anticancer therapies.\n6. Major surgery within 4 weeks before study treatment, or planned major surgery during the study period.\n7. Severe cardiovascular or cerebrovascular disease.\n8. Unresolved ≥ Grade 2 toxicity (CTCAE v5.0) from prior anticancer therapy, excluding alopecia.\n9. Known hypersensitivity to study drugs or their components.\n10. Any condition that may compromise patient safety or interfere with study evaluation, as judged by the investigator.","FEMALE","18 Years","75 Years",{"count":20,"type":21},49,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a single-arm, single-center prospective clinical study that will evaluate the clinical feasibility and efficacy of immunotherapy combined with chemotherapy in the neoadjuvant treatment of ovarian cancer, in order to explore the progression-free survival of the study population.",[27],"Ovarian Cancer",[27,29,30],"Neoadjuvant Therapy","Chemotherapy","NOT_YET_RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":21},"2026-06-06",{"date":39,"type":21},"2030-12-31",{"name":41,"class":42},"Obstetrics & Gynecology Hospital of Fudan University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":66,"locationsCount":43},"100641687","phase-2-cadonilimab-plus-chemotherapy-in-lacc-a-prospective-multicenter-randomized-phase-ii-trial-100641687","NCT07649174","Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial","Efficacy of Cadonilimab in Combination With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Cervical Cancer: A Prospective, Multicenter, Randomized Phase II Trial","Inclusion Criteria:\n\n1. Patients with previously untreated locally advanced cervical cancer, clinically staged as FIGO 2018 stage IB3, IIA2, IIB, or IIIC1r (tumor diameter \\>4 cm as assessed by contrast-enhanced pelvic MRI);\n2. Histologically or cytologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;\n3. Female patients aged ≥18 and ≤75 years;\n4. Willing and able to provide written informed consent and comply with study visits and protocol-required procedures;\n5. Eligible for radical hysterectomy with curative intent;\n6. At least one measurable lesion according to RECIST version 1.1;\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n8. Estimated life expectancy of at least 6 months;\n9. Women of childbearing potential must agree to use effective contraception throughout the study period. A negative serum or urine pregnancy test is required before study enrollment.\n\nExclusion Criteria:\n\n1. Histological subtypes other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, including but not limited to small cell carcinoma and clear cell carcinoma.\n2. Clinically significant unrecoverable hydronephrosis;\n3. CNS metastases or leptomeningeal disease;\n4. Active malignancy within 3 years prior to enrollment (with specified exceptions);\n5. Prior exposure to immune checkpoint inhibitors or other immunomodulatory anticancer therapies;\n6. Major surgery within 4 weeks before study treatment;\n7. Severe cardiovascular or cerebrovascular disease;\n8. Unresolved toxicities from previous anticancer therapy (\\> Grade 1, CTCAE v5.0);\n9. Known hypersensitivity to study drugs;\n10. Serious medical or psychiatric conditions that may interfere with study participation;\n11. Pregnancy.",{"count":52,"type":21},134,[24],"This is a prospective, multi-center, randomized controlled phase II clinical trial aimed at exploring the efficacy evaluation of cadilonilumab immunotherapy combined with chemotherapy for locally advanced cervical cancer.",[56],"Cervical Cancer",[58,59,60],"cervical cancer","Immunotherapy","Neoadjuvant therapy","2026-06-11",{"date":63,"type":35},"2026-06-16",{"date":37,"type":21},{"date":39,"type":21},{"name":41,"class":42},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100633178","efficacy-and-safety-of-intra-operative-dual-laparoscopy-and-neo-rectoscopy-for-bowel-endometriosis-the-lumen-01-trial-100633178","NCT07523308","Efficacy and Safety of Intra-operative Dual Laparoscopy and Neo-rectoscopy for Bowel Endometriosis: The LUMEN-01 Trial","Efficacy and Safety of Intra-operative Dual Laparoscopy and Neo-rectoscopy (IDLnR) Versus Conventional Laparoscopic Surgery for Bowel Endometriosis: A Multicenter, Open-Label, Randomized Controlled Trial (LUMEN-01)","LUMEN-01","Inclusion Criteria:\n\n* Premenopausal women aged 18 to 55 years.\n* Preoperative pelvic contrast-enhanced MRI and\u002For transrectal endosonography confirmed bowel endometriosis (BE) lesions involving the muscular layer of the intestinal wall, located in the rectum and\u002For sigmoid colon. Postoperative pathological diagnosis serves as the gold standard.\n* Pre-treatment LARS score \\> 20.\n* Eligible for laparoscopic surgery.\n* Voluntarily participated in this study and signed written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Presence of active inflammatory bowel disease, irritable bowel syndrome, or other similar conditions with disease flare-ups within the past 1 year.\n* Acute or severe infectious disease within 4 weeks prior to surgery.\n* History of malignant tumor, or highly suspected gynecological\u002Fgastrointestinal malignancy based on preoperative imaging or tumor marker tests.\n* American Society of Anesthesiologists (ASA) physical status classification ≥ Grade Ⅲ, or severe cardiac, pulmonary, hepatic, renal, or coagulation dysfunction that precludes general anesthesia and elective laparoscopic surgery.\n* Undergoing robot-assisted laparoscopic surgery or open laparotomy.\n* Currently participating in other clinical trials that may affect the outcome assessment of this study.\n* Previous participation in other interventional clinical trials that may affect the outcome assessment of this study.\n* History of colorectal resection and anastomosis or stoma surgery.\n* History of pelvic radiotherapy.","55 Years",{"count":77,"type":21},192,[79],"NA","The goal of this prospective, multicenter, randomized controlled trial is to compare the clinical efficacy and safety of intra-operative dual laparoscopy and neo-rectoscopy (IDLnR) versus conventional laparoscopy (CL) in patients with bowel endometriosis (BE) undergoing surgery. The primary objective is to assess differences in postoperative bowel function improvement at 6 months between the two groups.\n\nThe main questions it aims to answer are:\n\nIs there a significant difference in postoperative bowel function (primary endpoint) at 6 months postoperatively between IDLnR and CL groups? Do the two groups differ in secondary outcomes, including efficacy indicators (LARS score\u002Fcure rate\u002Fimprovement rate, CRADI-8, Wexner score, GIQLI, EHP-30, VAS pain reduction) and safety indicators (30-day severe complications, antibiotic use intensity, hospital stay \\>7 days)? Researchers will randomize BE surgical patients to IDLnR or CL groups, then compare the above primary and secondary endpoints to evaluate IDLnR's clinical value.\n\nParticipants will undergo either IDLnR or CL surgery for BE lesions, and be followed up to assess bowel function, quality of life, pain, and safety outcomes as specified.\n\nThis study will fill evidence gaps for IDLnR in BE surgery, support its standardized application, optimize BE treatment strategies, and aim for complete lesion resection, preserved intestinal function, and improved long-term patient quality of life.",[82,83,84],"Bowel Endometriosis","Endometriosis","Intestinal Endometriosis",[82,86,87,88,89],"Intra-operative Dual Laparoscopy and Neo-rectoscopy (IDLnR)","Efficacy","Safety","LARS","RECRUITING","2026-05-16",{"date":93,"type":35},"2026-05-19",{"date":95,"type":35},"2026-04-13",{"date":97,"type":21},"2028-05-31",{"name":41,"class":42},3,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":43},"100626334","early-phase-1-exploratory-clinical-study-of-cctl-in-combination-with-immunotherapy-for-advanced-gynecologic-malignancies-100626334","NCT07434284","Exploratory Clinical Study of cCTL in Combination With Immunotherapy for Advanced Gynecologic Malignancies","Exploratory Clinical Study of Tumor-Specific Cytotoxic T Lymphocyte Injection (cCTL) in Combination With Immunotherapy for Advanced Gynecologic Malignancies","Inclusion Criteria:\n\n1. Age between 18 and 75 years；\n2. Histologically or cytologically confirmed diagnosis of advanced ovarian cancer, cervical cancer, endometrial cancer, or other gynecological malignancies;\n3. Tumor patients with previous standard treatment failure, or those who refuse further chemotherapy, with a life expectancy of more than 3 months;\n4. ECOG performance status of 0-2;\n5. Patients of childbearing potential must use appropriate contraceptive methods (e.g., contraception or other methods of fertility control) before and during the trial;\n6. Ability to understand the trial and have signed the informed consent form;\n7. Ability to comply with the study protocol and follow-up procedures.\n\nExclusion Criteria:\n\n1. Receipt of any form of immunotherapy within the past 3 months;\n2. Required use of immunosuppressive agents;\n3. Receipt of tumor chemotherapy, radiotherapy, or second-degree or higher surgery within the past month;\n4. History of other cancers, except for in situ cervical cancer, treated squamous cell carcinoma, or bladder epithelial tumors (Ta and TIS), or other malignancies that have undergone radical treatment (at least 5 years prior to enrollment);\n5. White blood cell count \\\u003C 3×10\\^9\u002FL, platelet count \\\u003C 80×10\\^9\u002FL;\n6. AST and ALT \\> 3× upper limit of normal (ULN), total bilirubin \\> 2× ULN, for liver metastasis patients, AST and ALT \\> 6× ULN;\n7. Creatinine clearance \\\u003C 60 ml\u002Fmin;\n8. Coagulation dysfunction;\n9. Active bacterial or fungal infections (≥ grade 2 of NCI-CTC, 3rd edition);\n10. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA \\> 100 IU\u002FmL; positive for hepatitis C antibody with peripheral blood HCV RNA positive; positive for HIV antibody; positive CMV DNA; positive for syphilis;\n11. Diseases deemed inappropriate for enrollment by the investigator, including but not limited to severe liver, kidney, or metabolic diseases requiring drug treatment, uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease;\n12. Meeting any of the following heart-related standards:\n\n    * Screening heart ultrasound shows left ventricular ejection fraction (LVEF) \\\u003C 50%;\n    * Screening ECG at rest shows QTcF \\> 480 ms (female);\n    * Resting ECG shows any significant clinical arrhythmia, conduction, or morphological abnormalities (e.g., complete left bundle branch block, 2nd-3rd degree atrioventricular block, PR interval \\> 250 ms);\n    * Presence of factors increasing the risk of QTc interval prolongation or arrhythmic events, such as heart failure, hypokalemia, hypomagnesemia, congenital long QT syndrome, family history of long QT syndrome, or known medications that prolong QT intervals;\n13. Pregnant or breastfeeding women; women of childbearing potential must test negative for pregnancy within 7 days prior to enrollment;\n14. Drug abuse, clinical, psychological, or social factors that impair informed consent or study implementation；\n15. Known allergy to the study drug;\n16. Participation in other clinical trials within 1 month before enrollment;\n17. Inability to undergo apheresis or inability to establish peripheral venous access;\n18. Any uncertain factor that may affect the safety or compliance of the patient;\n19. Other conditions considered unsuitable for enrollment by the investigator.",{"count":5,"type":21},[109],"EARLY_PHASE1","This study is a single-arm, open-label, interventional, and exploratory clinical trial,the goal of which is to evaluate the safety and clinical efficacy of the novel tumor-specific cytotoxic T lymphocyte (cCTL) injection in combination with immunotherapy for the treatment of advanced gynecologic malignancies.The trial will also explore the preliminary efficacy and immunological characteristics of this therapy in a small sample of patients. 5-20 participants will be enrolled.",[112],"Advanced Gynecological Cancers","2026-02-19",{"date":115,"type":35},"2026-02-25",{"date":117,"type":21},"2026-02",{"date":119,"type":21},"2028-12",{"name":41,"class":42},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100621335","phase-2-melatonin-for-glycemic-control-in-gestational-diabetes-mellitus-100621335","NCT07369284","Melatonin for Glycemic Control in Gestational Diabetes Mellitus","Efficacy of Melatonin in Addition to Standard Care in Glycemic Control of Patients With Gestational Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial","MELODY","Inclusion Criteria:\n\n* Women aged 18 to 45 years\n* Singleton pregnancy\n* A diagnosis of GDM from a 75-g OGTT during 24 to 28 gestational weeks, according to the IADPSG criteria, with at least fasting plasma glucose (FPG) ≥ 5.1 mmol\u002FL\n* Intending to receive obstetric care and deliver in the study center\n* Willing and able to provide written informed consent and follow the study procedure\n\nExclusion Criteria:\n\n* Use of melatonin 1 month before pregnancy or\u002Fand during pregnancy\n* Night shift work or exposed to jetlag on a regular basis during pregnancy\n* Contraindications to melatonin use, including hypersensitive or allergic to melatonin\n* Use of antidepressive or antipsychotic medications which can interfere with melatonin metabolism and\u002For elimination, such as fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, quinolones, and other CYP1A2 inhibitors; carbamazepine, rifampicin, and other CYP1A2 inducers; and zaleplon, zolpidem, zopiclone, and other non-benzodiazepine hypnotics\n* Pre-pregnancy diabetes, including patients diagnosed with diabetes before conception, fasting plasma glucose ≥ 7.0 mmol\u002FL or HbA1c ≥ 6.5% in the first trimester, typical hyperglycemic symptoms or hyperglycemic crisis with random blood glucose ≥ 11.1 mmol\u002FL\n* Other major diseases before gestation, e.g. hypertensive disorders, rheumatology or malignant diseases, infected with hepatitis B or hepatitis C, chronic diseases leading to impaired heart, liver, or renal function\n* Major fetal anomalies","45 Years",{"count":131,"type":21},150,[24],"The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate whether melatonin supplementation improves glycemic control in pregnant women diagnosed with gestational diabetes mellitus (GDM).\n\nThe main question it aims to answer is:\n\nDoes melatonin supplementation help with glycemic control, especially in lowering fasting plasma glucose level?\n\nResearchers will compare melatonin to a placebo (a look-alike substance that contains no melatonin) to see if melatonin works to improve glycemic control.\n\nParticipants will:\n\n1. Take melatonin or a placebo every day after randomization until delivery\n2. Visit the antenatal clinic once every 1 to 2 weeks for follow-ups",[135],"Gestational Diabetes",[137,138,139],"Gestational diabetes","Melatonin","Fasting plasma glucose","2026-01-17",{"date":142,"type":35},"2026-01-27",{"date":117,"type":21},{"date":145,"type":21},"2027-08",{"name":41,"class":42},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100617444","multi-agent-llms-for-decision-support-in-cervical-cancer-during-pregnancy-100617444","NCT07318701","Multi-agent LLMs for Decision Support in Cervical Cancer During Pregnancy","Multi-agent Large Language Models for Multidisciplinary Decision Support in Cervical Cancer During Pregnancy","Inclusion Criteria:\n\n1. Pathologically confirmed diagnosis of cervical cancer.\n2. Confirmed intrauterine pregnancy status via ultrasound.\n3. Patients receiving initial treatment.\n4. Agreement to participate in the study with signed informed consent.\n\nExclusion Criteria:\n\n1. Previous treatment received for cervical cancer during pregnancy.\n2. Pathological pregnancy states (e.g., ectopic pregnancy).\n3. Inability or unwillingness to provide signed informed consent.",{"count":131,"type":21},[79],"The aim of this study is to develop an AI-assisted decision-making system based on multi-agent large language models and to evaluate its effectiveness and accuracy in the diagnosis and treatment of cervical cancer during pregnancy.",[56],[159,160,161],"Large Language Model","Cervical cancer during pregnancy","Multi-agent","2026-01-04",{"date":164,"type":35},"2026-01-06",{"date":166,"type":21},"2026-01-01",{"date":168,"type":21},"2026-10-30",{"name":41,"class":42},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":43},"100613061","phase-2-phase-ii-study-of-weekly-paclitaxelnab-paclitaxel-pembrolizumab-and-mirabegron-for-recurrent-ovarian-cancer-100613061","NCT07261683","Phase II Study of Weekly Paclitaxel\u002FNab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer","A Phase II Study Evaluating the Efficacy and Safety of Weekly Paclitaxel or Nab-Paclitaxel Combined With Pembrolizumab and Mirabegron in Patients With Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Has provided documented informed consent for the study.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.\n* Has received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence (note: Maintenance treatment following the front line treatment is permitted and counted together as part of the front line treatment).\n* Has a platinum-free interval (PFI) of \\\u003C 12 months if the last regimen received is a platinum-based, or a treatment-free interval (TFI) of \\\u003C 12 months if the last regimen received is a non-platinum-based.\n* Has measurable disease at baseline based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Has a life expectancy of ≥12 weeks.\n* Has provided a tumor tissue sample either collected from prior cytoreductive surgery or fresh newly obtained tumor tissue at screening.\n* Has adequate organ function.\n* Has not recovered from AEs to ≤ Grade 1 or prior treatment level due to a previously administered agent.\n\nExclusion Criteria:\n\n* Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.\n* Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen-4 \\[CTLA-4\\], tumor necrosis factor receptors OX-40 or CD137).\n* Has received prior systemic anticancer therapy including radiation therapy or maintenance therapy within 4 weeks before enrollment.\n* Has severe hypersensitivity (≥Grade 3) or uncontrolled hypertension to paclitaxel\u002Fnab-paclitaxel, pembrolizumab, mirabegron and any of their excipients.\n* Has undergone major surgery within 3 weeks before enrollment or has complications\u002Fsequelae that have not yet recovered.\n* Has a known additional malignancy that progressed or required active treatment within the last 5 years.\n* Is pregnant or breastfeeding.\n* Has a history of allogenic tissue\u002Fsolid organ transplant.\n* Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before enrollment.\n* Has a history of active autoimmune disease.\n* Has an active infection requiring systemic therapy.\n* Has a history of human immunodeficiency virus (HIV) infection.\n* Has a history of Hepatitis B or C virus infection.\n* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.",{"count":5,"type":21},[24],"The goal of this clinical trial is to learn if drug regimen weekly paclitaxel\u002Fnab-paclitaxel, pembrolizumab, and mirabegron works to treat relapsed ovarian cancer in adults. It will also learn about the safety of the drug regimen. The main questions it aims to answer are:\n\ni) Does drug weekly paclitaxel\u002Fnab-paclitaxel, pembrolizumab, and mirabegron reduce tumor volume? ii) What medical problems do participants have when taking drug weekly paclitaxel\u002Fnab-paclitaxel, pembrolizumab, and mirabegron?\n\nParticipants will:\n\ni) Take drug paclitaxel\u002Fnab-paclitaxel every week and pembrolizumab every 21 days with everyday mirabegron ii) Visit the clinic once every 2 months for checkups and tests iii) Keep a diary of their symptoms",[27,59,181],"Pembrolizumab",[183,184],"ovarian cancer","immunotherapy","2025-12-14",{"date":187,"type":35},"2025-12-19",{"date":189,"type":21},"2025-12",{"date":191,"type":21},"2028-11-30",{"name":41,"class":42},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":201,"enrollmentInfo":202,"targetDuration":204,"studyType":205,"phases":4,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},"100608528","a-multi-center-cohort-study-of-hydatidiform-mole-in-china-cn-hm-01-100608528","NCT07202728","A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)","Application and Promotion of the Whole-process Management and Precision Diagnosis and Treatment System for Hydatidiform Mole: a Multi-center Cohort Study in China (CN-HM-01)","CN-HM-01","Inclusion Criteria:\n\n1. Clinically or pathologically diagnosed as hydatidiform mole.\n2. Availability of complete medical records, including clinical and pathological data.\n3. No evidence of myometrial invasion or metastasis.\n4. Serum hCG levels normalized after uterine evacuation with at least 6 months of follow-up, OR diagnosed with postmolar gestational trophoblastic neoplasia (pGTN) during follow-up.\n5. No history of psychiatric disorders, serious infectious diseases, or immune system diseases (such as systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).\n6. Willing to participate in this study and sign the relevant informed consent form.\n\nExclusion Criteria:\n\n1. Missing clinical data.\n2. Loss to follow-up: Do not return to participating hospital for follow-up visits after uterine evacuation, or could not be contacted for subsequent monitoring of hCG changes.\n3. Concomitant malignancies or autoimmune deficiency disorders (e.g., systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).\n4. As determined by the investigator, the presence of medical, psychological, social, occupational, or other conditions that would violate the study protocol or impair the subject's ability to provide informed consent.","60 Years",{"count":203,"type":21},1489,"2 Years","OBSERVATIONAL","This observational study aims to establish a national cohort of patients with hydatidiform mole (molar pregnancy) to investigate its malignant transformation rate and malignant transformation mechanisms, with the goal of developing and promoting precision diagnosis and treatment models across China.",[208],"Hydatidiform Mole",[208,210],"Observational Study","2025-09-23",{"date":213,"type":35},"2025-10-02",{"date":215,"type":35},"2025-07-09",{"date":217,"type":21},"2030-08-30",{"name":41,"class":42},14,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":43},"100602955","phase-2-ivonescimab-combined-with-paclitaxel-and-cisplatin-as-neoadjuvant-therapy-followed-by-type-a-hysterectomy-in-stage-ib2-and-iia1-cervical-cancer-100602955","NCT07130240","Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer","Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer: A Phase II Trial","Inclusion Criteria:\n\n(1)Patients with FIGO 2018 stages IB2, IIA1 (2\\\u003C lesion ≤4 cm, confirmed by MRI); (2) Histologically confirmed cervical squamous cell carcinoma, cervical adenocarcinoma, or cervical adenosquamous carcinoma; (3)18-75 years old. (4) ECOG performance status score: 0-1. (5) No prior therapy received by the participant. (6)Expected survival period ≥6 months. (7) Women of childbearing potential must agree to use contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the study and for 6 months after the study ends. A negative serum or urine pregnancy test within 7 days before study enrollment is required, and the patient must not be breastfeeding.\n\n(8) Adequate organ function as defined by the protocol, with test samples collected within 7 days before the start of study treatment.\n\n(9) Participants voluntarily join the study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Histological subtypes or disease stages other than those permitted in inclusion criteria (1) and (2).\n2. Severe hypersensitivity (≥ Grade 3) to cisplatin, paclitaxel, Ivonescimab , and\u002For any of their excipients.\n3. Participation in another clinical trial within 4 weeks prior to enrollment.\n4. Administration of inactivated vaccines within 30 days before the first study treatment or planned vaccination during the study period.\n5. Treatment with systemic immunostimulants, colony-stimulating factors, interferons, interleukins, or combination vaccines within 6 weeks or 5 half-lives (whichever is shorter) before the first dose.\n6. Diagnosis of immunodeficiency or chronic systemic steroid therapy (exceeding 10 mg prednisone equivalent per day) or any other form of immunosuppressive therapy within 7 days before the first dose.\n7. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressive drugs) within the past 2 years.\n8. History of (non-infectious) pneumonitis requiring steroid treatment or current (non-infectious) pneumonitis.\n9. Active infection requiring systemic treatment.\n10. Known history of HIV infection.\n11. Known history of hepatitis B (defined as HBsAg reactivity) or active hepatitis C virus infection (defined as detectable HCV RNA \\[qualitative\\]).\n12. Known history of active tuberculosis (TB; Mycobacterium tuberculosis).\n13. Prior allogeneic tissue\u002Fsolid organ transplantation.\n14. Central nervous system metastases, such as brain metastases.\n15. Uncontrolled pleural or peritoneal effusion.\n16. Impaired mobility due to pathological fractures caused by bone metastases.\n17. Insufficient bone marrow function (without transfusion within 14 days): a) Absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL;b) Platelets \\\u003C100×10⁹\u002FL; c) Hemoglobin \\\u003C9 g\u002FdL.\n18. Liver abnormalities: a) ALT, AST, or ALP \\>2.5× upper limit of normal (ULN) without liver metastasis or \\>5×ULN with liver metastasis; b) Total bilirubin \\>1.5×ULN (\\>3×ULN in patients with Gilbert's syndrome); c) Decompensated cirrhosis (Child-Pugh class B or C); d) HBsAg-positive with HBV DNA ≥2000 IU\u002FmL (patients with HBsAg-positive and HBV DNA \\\u003C2000 IU\u002FmL must receive at least 2 weeks of anti-HBV therapy before the first dose); e) HCV antibody-positive with detectable HCV RNA.\n19. Kidney abnormalities: a) Serum creatinine \\>1.5×ULN or estimated creatinine clearance \\\u003C60 mL\u002Fmin using the Cockcroft-Gault formula; b) Urinalysis showing protein ≥++ and confirmed 24-hour urine protein \\>1.0 g; c) Renal failure requiring hemodialysis or peritoneal dialysis; d) History of nephrotic syndrome.\n20. Bleeding risk: a) Coagulation abnormalities: Activated partial hromboplastin time (APTT) or thrombin time (TT) \\>1.5×ULN, or international normalized ratio (INR) \\>1.5 (\\>2.5 for patients requiring anticoagulation therapy); b) History of bleeding (e.g., hemoptysis), coagulation disorders, or current use of warfarin, aspirin, low-molecular-weight heparin, or other antiplatelet agents (except for aspirin ≤100 mg\u002Fd for prophylaxis); c) Any signs or history of bleeding diathesis, regardless of severity; d) Active gastrointestinal bleeding, evidenced by hematemesis, hematochezia, or melena within the past 3 months, without resolution confirmed by endoscopy or colonoscopy; e) Any CTCAE ≥ Grade 3 bleeding or hemorrhagic event within 4 weeks before the first dose.\n21. Cardiovascular and cerebrovascular abnormalities: a) Any of the following within 12 months before the first dose: ≥ Grade 2 myocardial ischemia, yocardial infarction, arrhythmias, ≥ Grade 3 cardiac insufficiency, uncontrolled angina, coronary\u002Fperipheral artery bypass graft surgery, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack; b) Deep vein thrombosis or pulmonary embolism within 6 months before the first dose; c) Left ventricular ejection fraction (LVEF) \\\u003C50% assessed by Doppler ultrasound; d) Average QTc interval corrected by Fridericia's formula (QTcF) (based on at least 3 consecutive ECG readings): ≥470 ms for females; e) Uncontrolled hypertension (at least 2 measurements showing systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg).\n22. Other factors judged by the investigator as potentially affecting study results or leading to premature termination, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring concurrent treatment, significant laboratory abnormalities, or family\u002Fsocial factors that may compromise patient safety.",{"count":5,"type":21},[24],"Cervical cancer ranks fourth globally in both incidence and mortality rates, making early diagnosis and treatment of great significance. For early-stage cervical cancer, surgery remains the primary treatment approach. According to the latest NCCN guidelines, patients with Stage IA2 or IB1 cervical cancer confirmed by cone biopsy who meet Concerv or SHAPE criteria no longer require type C\u002FB hysterectomy. Instead, they may undergo type A hysterectomy with reduced surgical margins. However, patients with Stage IB2 or IIA1 tumors measuring 2-4 cm still require radical hysterectomy (type C). Radical hysterectomy carries high risks of postoperative complications and significantly impairs quality of life, including major vascular injury, urinary tract damage and dysfunction, lymphatic complications, and sexual dysfunction. Therefore, there is an imperative need to explore alternative or refined treatment approaches for Stage IB2\u002FIIA1 cervical cancer that ensure survival outcomes while reducing surgical morbidity and improving quality of life.\n\nNeoadjuvant therapy followed by scale-reduced surgery may represent a feasible strategy. Both immune escape and angiogenesis are core drivers of tumorigenesis and progression. Combined immunotherapy and anti-angiogenic therapy have demonstrated favorable antitumor efficacy and manageable safety profiles across multiple tumor types. Ivonescimab is a novel humanized tetrameric IgG-scFv bispecific antibody targeting PD-1 and VEGF. Mechanistically, PD-1 blockade reverses T-cell suppression while VEGF inhibition curbs neovascularization, yielding synergistic therapeutic enhancement. This agent has shown promising efficacy and safety in advanced non-small cell lung cancer, hepatocellular carcinoma, and recurrent glioblastoma, though clinical data in cervical cancer remain absent. Therefore, this prospective exploratory study aims to evaluate the efficacy and safety of neoadjuvant Ivonescimab combined with paclitaxel and cisplatin followed by type A hysterectomy for stage IB2\u002FIIA1 cervical cancer. The findings may provide novel insights for optimizing treatment paradigms-ensuring survival outcomes while preserving quality of life.",[231],"Cervical Cancers","2025-08-12",{"date":234,"type":35},"2025-08-19",{"date":236,"type":21},"2025-08-15",{"date":238,"type":21},"2030-08-31",{"name":41,"class":42},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":43},"100583584","phase-2-iparomlimab-and-tuvonralimab-combined-with-paclitaxel-and-cisplatin-as-neoadjuvant-therapy-for-cc-100583584","NCT06878222","Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC","Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for Cervical Cancer: a Phase 2 Umbrella Trial","Inclusion Criteria:\n\n1. Histologically confirmed cervical squamous cell carcinoma, cervical adenocarcinoma, or cervical adenosquamous carcinoma.\n2. -Arm 1 (Locally Advanced cervical cancer): Patients with locally advanced cervical cancer classified as FIGO 2018 stages IB3, IIA2, IIB, or IIICr (lesion ≥4 cm, confirmed by MRI).\n\n   * Arm2 (cervical cancer patients desiring fertility-sparing treatment): Patients with cervical cancer classified as FIGO 2018 stages IB2, IB3 (lesion ≤6 cm), IIA1, or IIA2 (lesion ≤6 cm) who have a strong desire to preserve fertility.\n\n     3）Planned to undergo surgical treatments of cervical cancer.\n\n4\\) -Arm 1 (Locally Advanced cervical cancer): Age 18-75 years.\n\n* Arm2 (cervical cancer patients desiring fertility-sparing treatment): Age 18-45 years.\n\n  5\\) ECOG performance status score: 0-1. 6) No prior immunotherapy received by the participant. 7) Expected survival period ≥6 months. 8) Women of childbearing potential must agree to use contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the study and for 6 months after the study ends. A negative serum or urine pregnancy test within 7 days before study enrollment is required, and the patient must not be breastfeeding.\n\n  9\\) Adequate organ function as defined by the protocol, with test samples collected within 7 days before the start of study treatment.\n\n  10\\) Participants voluntarily join the study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Histological subtypes or disease stages other than those permitted in inclusion criteria 1) and 2).\n2. Severe hypersensitivity (≥ Grade 3) to cisplatin, paclitaxel, iparomlimab and tuvonralimab, and\u002For any of their excipients.\n3. Participation in another clinical trial within 4 weeks prior to enrollment.\n4. Administration of inactivated vaccines within 30 days before the first study treatment or planned vaccination during the study period.\n5. Treatment with systemic immunostimulants, colony-stimulating factors, interferons, interleukins, or combination vaccines within 6 weeks or 5 half-lives (whichever is shorter) before the first dose.\n6. Diagnosis of immunodeficiency or chronic systemic steroid therapy (exceeding 10 mg prednisone equivalent per day) or any other form of immunosuppressive therapy within 7 days before the first dose.\n7. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressive drugs) within the past 2 years.\n8. History of (non-infectious) pneumonitis requiring steroid treatment or current (non-infectious) pneumonitis.\n9. Active infection requiring systemic treatment.\n10. Known history of HIV infection.\n11. Known history of hepatitis B (defined as HBsAg reactivity) or active hepatitis C virus infection (defined as detectable HCV RNA \\[qualitative\\]).\n12. Known history of active tuberculosis (TB; Mycobacterium tuberculosis).\n13. Prior allogeneic tissue\u002Fsolid organ transplantation.\n14. Central nervous system metastases, such as brain metastases.\n15. Uncontrolled pleural or peritoneal effusion.\n16. Impaired mobility due to pathological fractures caused by bone metastases.\n17. Insufficient bone marrow function (without transfusion within 14 days): a) Absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL;b) Platelets \\\u003C100×10⁹\u002FL; c) Hemoglobin \\\u003C9 g\u002FdL.\n18. Liver abnormalities: a) ALT, AST, or ALP \\>2.5× upper limit of normal (ULN) without liver metastasis or \\>5×ULN with liver metastasis; b) Total bilirubin \\>1.5×ULN (\\>3×ULN in patients with Gilbert's syndrome); c) Decompensated cirrhosis (Child-Pugh class B or C); d) HBsAg-positive with HBV DNA ≥2000 IU\u002FmL (patients with HBsAg-positive and HBV DNA \\\u003C2000 IU\u002FmL must receive at least 2 weeks of anti-HBV therapy before the first dose); e) HCV antibody-positive with detectable HCV RNA.\n19. Kidney abnormalities: a) Serum creatinine \\>1.5×ULN or estimated creatinine clearance \\\u003C60 mL\u002Fmin using the Cockcroft-Gault formula; b) Urinalysis showing protein ≥++ and confirmed 24-hour urine protein \\>1.0 g; c) Renal failure requiring hemodialysis or peritoneal dialysis; d) History of nephrotic syndrome.\n20. Bleeding risk: a) Coagulation abnormalities: Activated partial hromboplastin time (APTT) or thrombin time (TT) \\>1.5×ULN, or international normalized ratio (INR) \\>1.5 (\\>2.5 for patients requiring anticoagulation therapy); b) History of bleeding (e.g., hemoptysis), coagulation disorders, or current use of warfarin, aspirin, low-molecular-weight heparin, or other antiplatelet agents (except for aspirin ≤100 mg\u002Fd for prophylaxis); c) Any signs or history of bleeding diathesis, regardless of severity; d) Active gastrointestinal bleeding, evidenced by hematemesis, hematochezia, or melena within the past 3 months, without resolution confirmed by endoscopy or colonoscopy; e) Any CTCAE ≥ Grade 3 bleeding or hemorrhagic event within 4 weeks before the first dose.\n21. Cardiovascular and cerebrovascular abnormalities: a) Any of the following within 12 months before the first dose: ≥ Grade 2 myocardial ischemia, yocardial infarction, arrhythmias, ≥ Grade 3 cardiac insufficiency, uncontrolled angina, coronary\u002Fperipheral artery bypass graft surgery, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack; b) Deep vein thrombosis or pulmonary embolism within 6 months before the first dose; c) Left ventricular ejection fraction (LVEF) \\\u003C50% assessed by Doppler ultrasound; d) Average QTc interval corrected by Fridericia's formula (QTcF) (based on at least 3 consecutive ECG readings): ≥470 ms for females; e) Uncontrolled hypertension (at least 2 measurements showing systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg).\n22. Other factors judged by the investigator as potentially affecting study results or leading to premature termination, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring concurrent treatment, significant laboratory abnormalities, or family\u002Fsocial factors that may compromise patient safety.",{"count":248,"type":21},35,[24],"Currently, the survival rate of locally advanced cervical cancer is low, posing a significant challenge in the treatment of cervical cancer. Radical chemoradiotherapy is considered the standard treatment for patients with locally advanced cervical cancer. However, 23.3% to 34.4% of patients still experience recurrence or subsequent metastasis. Radical surgery following neoadjuvant chemotherapy is an alternative to concurrent chemoradiotherapy, but it also has limitations: for approximately 9.8% to 30.6% of patients who do not respond to neoadjuvant chemotherapy, effective local treatment may be delayed. Additionally, more than 30% of patients still require adjuvant radiotherapy or chemoradiotherapy after surgery, significantly increasing the risk of complications. Therefore, there is an urgent need to explore alternative or improved treatment methods for neoadjuvant chemotherapy in locally advanced cervical cancer.\n\nAn increasing number of women are being diagnosed with cervical cancer during their childbearing years, many of whom have a desire to preserve their fertility. For selected patients with stage IB2 cervical cancer, options include abdominal radical trachelectomy or radical trachelectomy following neoadjuvant chemotherapy. However, compared to conservative surgeries such as conization or partial cervical resection, radical trachelectomy is associated with less favorable fertility rates and pregnancy outcomes, with significantly higher rates of infertility, miscarriage, and preterm birth. For patients with stage IB3 or IIA1-IIA2 cervical cancer, the current standard surgical approach is radical hysterectomy, which does not preserve fertility. Current research suggests that neoadjuvant chemotherapy can shrink tumor size, decrease lymph node and distant metastases, and reduce the need for postoperative adjuvant radiotherapy. This offers hope for young cervical cancer patients who wish to preserve fertility, as it may reduce tumor size, thereby allowing for less extensive fertility-sparing surgery, improving pregnancy outcomes, or even making fertility-sparing surgery a viable option.\n\nIn recent years, immunotherapy has gradually become a research hotspot in cancer treatment. Anti-PD-1\u002FPD-L1 monoclonal antibodies, as a type of immunotherapy drug, have demonstrated promising anti-tumor efficacy and low side effects in clinical trials. Iparomlimab and Tuvonralimab is a novel therapeutic biological product targeting both PD-1 and CTLA-4. It is composed of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4) expressed in a fixed ratio and has shown significant efficacy in cervical cancer patients. Therefore, given the urgent need to improve neoadjuvant therapy for locally advanced cervical cancer and fertility-preserving neoadjuvant therapy for early-stage cervical cancer patients, this study is being conducted to explore and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab combined with paclitaxel and cisplatin as neoadjuvant therapy for cervical cancer. Additionally, the study aims to investigate the relationship between tumor-related biomarkers and the risk of recurrence.",[231],[58,253,254,184,255],"neoadjuvant therapy","Iparomlimab and Tuvonralimab","fertility-preserving","2025-03-30",{"date":258,"type":35},"2025-04-01",{"date":260,"type":35},"2025-03-15",{"date":262,"type":21},"2030-03-31",{"name":41,"class":42},{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":43},"100585574","a-phase-i-clinical-trial-of-car-t-cells-for-advanced-gynecological-solid-tumors-100585574","NCT06904131","A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors","A Phase I Clinical Trial of MUC1-targeted CAR-T Cells with PD1 Nanobody MSLN Dual-target for Advanced Gynecological Solid Tumors","inclusion criteria\n\n1. Patients with gynecological solid tumors diagnosed by histopathology, with tumor tissue sample MUC1 expression rate ≥50% or MSLN expression rate ≥50%, PD-L1 positive expression, and sample source within 2 years;\n2. Patients with advanced gynecological solid tumors who have failed standard treatment or are intolerant to such treatment and have no standard effective treatment options;\n3. Females aged 18 to 70 years (inclusive);\n4. Estimated survival time ≥ 3 months;\n5. ECOG performance status score of 0 to 1 at screening and baseline;\n6. Good organ and bone marrow function:\n\n   1. The researcher assesses sufficient bone marrow function to receive lymphocyte-depleting chemotherapy: Neutrophil count ≥1.5 × 10\\^9\u002FL, lymphocyte count ≥0.5 × 10\\^9\u002FL;\n   2. Platelet count ≥90 × 10\\^9\u002FL;\n   3. Hemoglobin ≥90 g\u002FL (no blood transfusion or no erythropoietin-dependent within 7 days);\n   4. Total bilirubin ≤2 times the upper limit of normal value;\n   5. Serum creatinine ≤1.5 times the upper limit of normal value;\n   6. Transaminase (AST, ALT) ≤2.5 times the upper limit of normal value (if liver metastasis is present, 5 times the upper limit of normal value);\n   7. International Normalized Ratio (INR) or prothrombin time (PT) ≤1.5 times the upper limit of normal value;\n   8. Pulmonary function: ≤ CTCAE grade 1 dyspnea and SaO2 ≥ 91% in room air;\n   9. Cardiac function: Echocardiogram or radionuclide ventriculography (MUGA) assessment left ventricular ejection fraction (LVEF) ≥50% within 1 month of enrollment.\n\nexclusion criteria\n\n1. Participants who have undergone other anti-tumor treatments not allowed by the protocol within 1 month before CAR-T infusion (including radiotherapy, chemotherapy, small molecules, biological treatment, or immunotherapy, other research drugs);\n2. Participants who have previously received targeted therapy against MUC1 or MSLN, or cellular therapy, or any gene therapy products (including CAR-T cell therapy) or any T cell therapy at home or abroad;\n3. Pregnant or breastfeeding women;\n4. AIDS virus, syphilis seroreactivity positive; hepatitis B surface antigen positive, or hepatitis B core antibody positive and hepatitis B virus DNA copies higher than the detection limit or greater than or equal to 1000 copies\u002FmL; or hepatitis C virus infection;\n5. Any uncontrollable active infection, coagulopathy, or any other major disease;\n6. Patients with active autoimmune diseases being treated, organ transplantation and other immune-related diseases, or long-term use of immunosuppressive drugs such as glucocorticoids: a. Glucocorticoids cannot be discontinued within 72 hours before CAR-T cell infusion; b. Immunosuppressive agents other than glucocorticoids cannot be discontinued ≥4 weeks before enrollment;\n7. Patients with severe cardiopulmonary insufficiency, uncontrolled hypertension, any of the following cardiovascular disease histories within the past 6 months: III or IV heart failure defined by the New York Heart Association (NYHA), cardiac catheterization or stent, myocardial infarction, unstable angina, or other clinically significant heart disease;\n8. Patients with confirmed brain metastasis, or those with a history of or current central nervous system disease, such as epileptic seizures, cerebrovascular ischemia\u002Fhemorrhage, dementia, encephalopathy, or any autoimmune disease associated with the central nervous system;\n9. Patients with high risk of bleeding or perforation;\n10. Patients who underwent major surgery or significant trauma within 4 weeks before single collection;\n11. Patients with other malignant tumors within 3 years or concurrently (except for skin basal cell carcinoma, cervical\u002Fbreast cancer in situ, etc.);\n12. Any other conditions deemed unsuitable for participation in the study by the investigator.","70 Years",{"count":5,"type":21},[79],"Screening patients who meet the criteria for peripheral blood mononuclear cell (PBMC) isolation and cell preparation. Based on the status of cell preparation and mutual agreement between the researcher and the participant, the date of reinfusion (Day 0) is determined. From Day -5 to Day -3, the participant receives a conditioning regimen with cyclophosphamide and antithymocyte globulin. After recovery for two days (Day -2 and Day -1), on Day 0, the participant receives reinfusion of BZE2203 (dose determined according to the dose-escalation requirements). The safety observation period lasts for 28 days, and clinical efficacy is assessed from Day 28 to Day 34. After comprehensive judgment, the second course of cell therapy is selected. Follow-up observations and evaluations are conducted once every three months, with follow-up visits once a year and telephone follow-ups once every two months.",[276],"Gynecological Solid Tumors","2025-03-24",{"date":258,"type":35},{"date":280,"type":21},"2025-05-11",{"date":282,"type":21},"2027-12-31",{"name":41,"class":42},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":302,"leadSponsor":304,"locationsCount":43},"100576912","phase-2-pegylated-liposomal-doxorubicin-plus-adebrelimab-with-or-without-mirabegron-in-relapsed-ovarian-cancer-100576912","NCT06791460","Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer","Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer: a Randomized, Controlled, Open-label Trial","Inclusion Criteria:\n\n* Has provided documented informed consent for the study.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.\n* Has received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence (note: Maintenance treatment following the front line treatment is permitted and counted together as part of the front line treatment).\n* Has a platinum-free interval (PFI) of \\\u003C 12 months if the last regimen received is a platinum-based, or a treatment-free interval (TFI) of \\\u003C 12 months if the last regimen received is a non-platinum-based.\n* Has measurable disease at baseline based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Has a life expectancy of ≥12 weeks.\n* Has provided a tumor tissue sample either collected from prior cytoreductive surgery or fresh newly obtained tumor tissue at screening.\n* Has adequate organ function.\n* Has not recovered from AEs to ≤ Grade 1 or prior treatment level due to a previously administered agent.\n\nExclusion Criteria:\n\n* Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.\n* Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen-4 \\[CTLA-4\\], tumor necrosis factor receptors OX-40 or CD137) or has participated in prior adebrelimab studies.\n* Has received prior systemic anticancer therapy including radiation therapy or maintenance therapy within 4 weeks before randomization.\n* Has severe hypersensitivity (≥Grade 3) or uncontrolled hypertension to pegylated liposomal doxorubicin, adebrelimab, mirabegron and any of their excipients.\n* Has undergone major surgery within 3 weeks before randomization or has complications\u002Fsequelae that have not yet recovered.\n* Has a known additional malignancy that progressed or required active treatment within the last 5 years.\n* Is pregnant or breastfeeding.\n* Has a history of allogenic tissue\u002Fsolid organ transplant.\n* Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization.\n* Has a history of active autoimmune disease.\n* Has an active infection requiring systemic therapy.\n* Has a history of human immunodeficiency virus (HIV) infection.\n* Has a history of Hepatitis B or C virus infection.\n* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.",{"count":292,"type":21},296,[24,294],"PHASE3","The goal of this clinical trial is to learn if drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron works to treat relapsed ovarian cancer in adults. It will also learn about the safety of drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron. The main questions it aims to answer are:\n\nDoes drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron reduce tumor volume? What medical problems do participants have when taking drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron?\n\nResearchers will compare drug regimen pegylated liposomal doxorubicin and adebrelimab with mirabegron to a drug regimen pegylated liposomal doxorubicin and adebrelimab without mirabegron to see which drug regimen works better to treat relapsed ovarian cancer.\n\nParticipants will:\n\nTake drug pegylated liposomal doxorubicin and adebrelimab every 21 days with or without everyday mirabegron Visit the clinic once every 2 months for checkups and tests Keep a diary of their symptoms",[297],"Ovarian Cancer Recurrent","2025-03-17",{"date":300,"type":35},"2025-03-18",{"date":300,"type":21},{"date":303,"type":21},"2030-02-14",{"name":41,"class":42},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":323,"locationsCount":43},"100583582","ctdna-guided-first-line-immuno-de-escalation-therapy-for-ivb-stage-and-recurrent-cervical-cancer-100583582","NCT06878196","ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer","ctDNA-guided First-line Immuno-de-escalation Therapy for Stage IVB and Recurrent Cervical Cancer: A Prospective, Single-arm, Multicenter Phase II Clinical Trial","Inclusion Criteria:\n\n* Clinically diagnosed as stage IVB primary treatment and recurrent cervical cancer patients (this relapse has not been systematically treated); Histologically or cytologically confirmed recurrent or metastatic cervical cancer, pathological types are squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; Age ≥18 years old and ≤75 years old, female; Signed written informed consent form, and able to comply with the visitation and related procedures specified in the protocol; Has not received systematic treatment for primary stage IVB or this relapse; Has at least one measurable lesion (RECIST 1.1 version); ECOG performance status 0-1; Estimated survival time ≥3 months; Menopausal trial participants must agree to use effective contraceptive measures during the trial; pregnant women must have a negative serum or urine pregnancy test.\n\nGood organ function:\n\nHematology (subjects will not be allowed to receive blood transfusion or growth factor support within 7 days of starting the study): i. Neutrophil count (ANC) ≥ 1.5 × 10\\^9 \u002FL (1,500\u002Fmm\\^3); ii. Platelet count ≥ 100 × 10\\^9 \u002FL (100,000\u002Fmm\\^3); iii. Hemoglobin ≥ 9.0 g\u002FdL.\n\nKidney:\n\ni. Serum creatinine (SCr) ≤ 1.5 × ULN or creatinine clearance (CrCl) calculated value ≥ 50 mL\u002Fmin \\* using the Cockcroft-Gault formula to calculate CrCl; if cisplatin is planned to be used in combination, CrCl ≥ 60 mL\u002Fmin;\n\nLiver:\n\ni. Serum total bilirubin (TBil) ≤ 1.5 × ULN; for subjects with liver metastasis or with evidence of Gilbert's disease, TBil ≤ 3 × ULN; ii. AST and ALT ≤2.5 × ULN; for subjects with liver metastasis, AST and ALT ≤ 5 × ULN; iii. Serum albumin ≥ 28 g\u002FL.\n\nCoagulation:\n\ni. International normalized ratio and activated partial thromboplastin time ≤ 1.5 × ULN (unless the subject is undergoing anticoagulant treatment, and the coagulation parameters (PT\u002FINR and aPTT) are within the expected range of anticoagulant treatment at screening) 11. Menopausal trial participants must agree to use effective contraceptive measures during the trial; pregnant women must have a negative serum or urine pregnancy test.\n\nExclusion Criteria:\n\n* Patients with pathological types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (e.g., small cell carcinoma, clear cell carcinoma, etc.).\n\nPatients with clinically significant hydronephrosis of the renal pelvis, judged by the investigator as not relievable by nephrostomy or ureteral stent placement. Presence of central nervous system metastasis or carcinomatous meningitis.\n\nPatients with other active malignant tumors within 3 years prior to the first dose of medication, except for locally curable tumor types that are considered cured, such as cutaneous squamous cell carcinoma, cutaneous basal cell carcinoma, superficial bladder carcinoma, primary breast cancer.\n\nWithin 4 weeks prior to the first dose of medication, patients who have received the last cycle of concurrent radiochemotherapy aimed at radical or neoadjuvant\u002Fadjuvant purposes; within 2 weeks prior to the first dose of medication, patients who have received palliative radiotherapy (e.g., for bone metastasis); within 2 weeks prior to the first dose of medication, patients who have received drugs with immunomodulatory effects (e.g. thymic peptides, interferons, interleukin-2); within 2 weeks prior to the first dose of medication, patients who have received traditional Chinese patent medicine for anti-tumor adaptation.\n\nPatients who have previously received immune checkpoint inhibitors (e.g., anti PD-1 antibodies, anti PD-L1 antibodies, anti CTLA-4 antibodies, etc.) or any treatment targeting tumor immune mechanisms (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40 targets, etc.).\n\nWithin 4 weeks prior to the first dose of medication, patients who have undergone major surgery (determined by the investigator), open biopsy, or significant trauma; or patients who require major surgical treatment during the study period and cannot tolerate medication.\n\nPatients with active or potentially recurrent autoimmune diseases; the following are excluded: vitiligo, alopecia, psoriasis, or eczema that do not require systemic treatment; hypothyroidism caused by autoimmune thyroiditis, requiring only stable dose hormone replacement treatment; type I diabetes requiring only stable dose insulin replacement treatment.\n\nWithin 14 days prior to the first dose of medication, patients who require systemic treatment with \\>10 mg\u002Fday prednisone or equivalent doses of glucocorticoid hormones or other immunosuppressive drugs; within 4 weeks prior to the first dose of medication, patients with severe infections, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia.\n\nActive or potentially recurrent systemic infections requiring systemic treatment (including active pulmonary tuberculosis and active syphilis infection), and who have used systemic antibacterial, antiviral, or antifungal drugs within 2 weeks prior to the first dose of medication; note: antiviral drugs for hepatitis B are excluded.\n\nActive hepatitis B virus carriers, non-active or asymptomatic hepatitis B virus (HBV) carriers (hepatitis B surface antigen \\[HBsAg\\] positive) with HBV DNA \\>1000 IU\u002FmL, and active hepatitis C virus carriers (note: non-active or asymptomatic carriers, after treatment and stable hepatitis B carriers with HBV DNA ≤ 1000 IU\u002FmL are allowed to enroll). Patients with cured hepatitis C are allowed to enroll.\n\nPatients with active or a history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), active diverticulitis, presence of clinical manifestations of gastrointestinal obstruction, or those requiring routine parenteral fluid, parenteral nutrition, or nasogastric tube placement.\n\nSevere cerebrovascular or cerebrovascular diseases. Previous antineoplastic treatment toxicity not resolved, defined as toxicity not recovered to NCI CTCAE v5.0 ≤1 grade, or the levels specified in the inclusion\u002Fexclusion criteria (except for alopecia).\n\nPatients allergic to the investigational medication. Any condition that the investigator believes may pose a risk to receiving study medication treatment, or may interfere with the evaluation of the study medication or the safety or interpretation of the results of the study (e.g. patients with other serious diseases or psychiatric disorders, etc.)",{"count":5,"type":21},[79],"This study aims to evaluate the clinical feasibility of first-line immunochemotherapy for stage IVB and recurrent cervical cancer guided by circulating tumor DNA (ctDNA), in order to explore the optimal treatment duration or criteria for discontinuation of first-line immunotherapy in patients with stage IVB cervical cancer or recurrent cervical cancer. To ensure the quality of the study, before the study begins, the research applicant and participants jointly discuss and formulate the research plan. Necessary steps should be taken during the design and implementation stages of the study to ensure that the collected data is accurate, consistent, complete, and credible.",[316],"Uterine Cervical Neoplasm","2025-03-13",{"date":319,"type":35},"2025-03-14",{"date":321,"type":21},"2025-03-10",{"date":119,"type":21},{"name":41,"class":42},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":43},"100580678","exploratory-study-on-nirfi-technology-combined-with-icg-guided-cervical-cancer-lymph-node-metastasis-100580678","NCT06840418","Exploratory Study on NIRFI Technology Combined with ICG Guided Cervical Cancer Lymph Node Metastasis","Exploratory Study on Near-Infrared Fluorescence Imaging Technology Combined with Indocyanine Green Guided Cervical Cancer Lymph Node Metastasis","Inclusion Criteria:\n\n1. Patients with primary cervical cancer stages I to III, with no restrictions on pathological type.\n2. Age ≥18 years old and ≤75 years old.\n3. Patients who have undergone radical hysterectomy\u002Fmodified radical hysterectomy (referring to the Q-M surgery classification, with surgical methods of type B and type C) + pelvic lymph node dissection.\n4. Patients with complete preoperative clinical and postoperative pathological data.\n5. Normal liver and kidney function and within the normal range of blood routine tests (specific details are as follows): Hemoglobin \\>60 g\u002FL; Platelets \\>70 \\* 10\\^9\u002FL; White blood cells \\>3 \\* 10\\^9\u002FL; Creatinine \\\u003C50 mg\u002FdL; Abnormal liver enzyme indicators ≤3 items; The highest value of liver enzymes does not exceed three times the corresponding normal value.\n6. No history of other malignant tumors within 5 years.\n7. Not pregnant.\n8. Performance status: Karnofsky score ≥60 points or ECOG score 0 to 1 points.\n9. Volunteers who willingly join this study, sign the informed consent form, have good compliance, and cooperate with follow-up visits.\n10. No mental illness or other serious infectious diseases or immune system diseases (such as lupus erythematosus, myasthenia gravis, HIV infection, etc.)\n\nExclusion Criteria:\n\n1. Patients with allergies to ICG or iodine. Individuals with contraindications to various surgeries who cannot undergo surgery.\n2. Patients with recurrent cervical cancer.\n3. Patients who have participated in other clinical trials within the past 3 months.\n4. Other conditions deemed unsuitable for inclusion in this study by the 5.investigator, or patients with other underlying diseases that may confound the study results.\n\n6.Patients who are assessed preoperatively as having systemic and organ conditions that are unlikely to tolerate surgery.\n\n7.Patients or guardians who are unwilling or unable to provide written informed consent or comply with subsequent follow-up requirements.",{"count":332,"type":21},15,[79],"The goal of this exploratory study is to exploring the lymph node metastasis, tumor margin, blood vessels, ureters, and nerve imaging in cervical cancer surgery using near-infrared fluorescence imaging technology combined with indocyanine green, and establishing an artificial intelligence model for predicting lymph node metastasis of cervical cancer to guide the advancement of refined surgical procedures.And the focus of this study is to investigate the situation of pelvic lymph node metastasis.The sole medication used in this experiment is the fluorescent contrast agent that has been clinically used for over 40 years - Indocyanine Green (ICG).Subsequent pathology results after the surgery will be used as the gold standard to determine the detection rate of lymph node metastasis and the accuracy of the complete resection rate of the surgical margin in cervical cancer.The researchers will also follow up on the quality of life of patients after the surgery.\n\nThe main question it aims to answer is:\n\ncan artificial intelligence multimodal fusion prediction models improve the accuracy of preoperative diagnosis of pelvic lymph node metastasis in cervical cancer? The researchers compared the AI multimodal fusion prediction model with traditional imaging physician assessments to see if the prediction model could yield more accurate lymph node metastasis determinations. Participants will undergo pelvic MRI after pathologically confirming a diagnosis of cervical cancer, and the results will be used to determine pelvic lymph node metastasis status by the predictive model and the imaging physician, respectively. Subsequent pathology results after surgical lymph node clearance will be used as the gold standard to determine the accuracy of the two preoperative lymph node diagnostic modalities.",[336],"Uterine Cervical Neoplasms","2025-02-17",{"date":339,"type":35},"2025-02-21",{"date":341,"type":35},"2025-01-01",{"date":343,"type":21},"2027-12",{"name":41,"class":42},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":43},"100557682","a-prospective-cohort-study-comparing-ai-prediction-model-with-imaging-assessment-to-diagnose-lymph-node-metastasis-in-cervical-cancer-100557682","NCT06541288","A Prospective Cohort Study Comparing AI Prediction Model With Imaging Assessment to Diagnose Lymph Node Metastasis in Cervical Cancer","A Prospective Cohort Study Comparing Artificial Intelligence Multimodal Fusion Prediction Models With Conventional Imaging Assessment for the Diagnosis of Pelvic Lymph Node Metastasis in Cervical Cancer","Inclusion criteria:\n\n1. patients with preoperative diagnosis of invasive cervical cancer stage I-III, with any type of pathology, and patients who underwent radical\u002Fmodified radical cervical cancer surgery + pelvic lymph node dissection in our hospital or sub-center;\n2. Age ≥18 years and ≤80 years;\n3. patients who underwent preoperative pelvic MRI (plain\u002Fenhanced) imaging in our hospital or sub-centers.\n\nExclusion criteria:\n\n1. patients during pregnancy or lactation, patients with abortion within 42 days;\n2. patients who are undergoing or have undergone preoperative neoadjuvant chemotherapy or radiotherapy for this cervical cancer;\n3. Patients with other malignant tumors within 5 years;\n4. Combination of other underlying diseases that may lead to enlarged pelvic lymph nodes;\n5. patients whose preoperative pelvic MRI date is more than 1 month from the day of surgery;\n6. poor quality imaging images that are unrecognizable.","80 Years",{"count":354,"type":21},230,[79],"The goal of this prospective cohort study is to learn whether artificial intelligence multimodal fusion prediction models are effective in diagnosing pelvic lymph node metastasis in cervical cancer. The main question it aims to answer is: can artificial intelligence multimodal fusion prediction models improve the accuracy of preoperative diagnosis of pelvic lymph node metastasis in cervical cancer? The researchers compared the AI multimodal fusion prediction model with traditional imaging physician assessments to see if the prediction model could yield more accurate lymph node metastasis determinations. Participants will undergo pelvic MRI after pathologically confirming a diagnosis of cervical cancer, and the results will be used to determine pelvic lymph node metastasis status by the predictive model and the imaging physician, respectively. Subsequent pathology results after surgical lymph node clearance will be used as the gold standard to determine the accuracy of the two preoperative lymph node diagnostic modalities.",[336],"2024-08-06",{"date":360,"type":35},"2024-08-07",{"date":362,"type":21},"2024-08",{"date":343,"type":21},{"name":41,"class":42},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":372,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":374,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":4},"100555135","neovaginoplasty-using-photoinduced-imine-crosslink-hydrogel-in-mrkh-patients-100555135","NCT06508151","Neovaginoplasty Using Photoinduced-imine-crosslink Hydrogel in MRKH Patients","Study on the Effectiveness and Safety of Neovaginoplasty Using Photoinduced-imine-crosslink Hydrogel in Patients With Mayer-Rokitansky-Kuster-Hauser Syndrome","Inclusion Criteria:\n\n1. Diagnosed with MRKH syndrome;\n2. Without previous related treatments; 3)18-35 years old;\n\n4)Voluntary agreement to participate in the study, sign the informed consent form, and demonstrate good compliance with follow-up.\n\nExclusion Criteria:\n\n1. With any previous artificial colpoplasty or other related treatment;\n2. With history of diabetes or systemic immune system disease.","35 Years",{"count":5,"type":21},[79],"Evaluating the effectiveness and safety of neovaginoplasty using photoinduced-imine-crosslink hydrogel in patients with MRKH syndrome by comparing the differences in the degree of squamous epithelialization, vaginal length and width, and sexual life quality.",[377],"Mayer Rokitansky Kuster Hauser Syndrome",[379,380,381],"Photoinduced-imine-crosslink hydrogel","MRKH syndrome","Neovaginoplasty","2024-07-12",{"date":384,"type":35},"2024-07-18",{"date":386,"type":21},"2024-08-01",{"date":388,"type":21},"2026-06-30",{"name":41,"class":42},{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":352,"enrollmentInfo":396,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":398,"conditions":399,"keywords":402,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":410,"locationsCount":43},"100550578","development-of-an-imaging-prediction-model-for-pelvic-lymph-node-metastasis-of-cervical-cancer-using-artificial-intelligence-techniques-100550578","NCT06448897","Development of an Imaging Prediction Model for Pelvic Lymph Node Metastasis of Cervical Cancer Using Artificial Intelligence Techniques.","Inclusion criteria:\n\n1. patients with preoperative diagnosis of invasive cervical cancer stage I-III, with any type of pathology, and patients who underwent radical\u002Fmodified radical cervical cancer surgery + pelvic lymph node dissection in our hospital.\n2. Age ≥18 years old and ≤80 years old\n3. patients with complete preoperative pelvic MRI images and postoperative pathology and clinical data in our hospital\n\nExclusion criteria:\n\n1. Patients during pregnancy or breastfeeding, patients within 42 days of abortion\n2. Patients who have received neoadjuvant chemotherapy or radiotherapy before surgery for this previous cervical cancer\n3. Patients with other malignant tumors within 5 years\n4. Combination of other underlying diseases that may lead to enlarged pelvic lymph nodes\n5. Imaging report more than 1 month prior to surgery\n6. Poor image quality and unrecognizable",{"count":397,"type":21},4000,"This study is a retrospective exploratory trial conducted at a single center, aiming to develop and validate a preoperative lymphatic metastasis model for cervical cancer using artificial intelligence deep learning. The model is trained using preoperative imaging and postoperative pathological findings of cervical cancer patients, with the goal of enhancing the accuracy of lymphatic metastasis prediction through preoperative imaging and offering insights for treatment decisions.",[56,400,401],"Lymph Node Metastasis","Artificial Intelligence",[56,400,403],"Artificial Interlligence","2024-06-03",{"date":406,"type":35},"2024-06-07",{"date":408,"type":35},"2024-02-01",{"date":189,"type":21},{"name":41,"class":42},{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":271,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":4},"100525955","phase-2-adjuvant-chemoradiotherapy-followed-by-zimberelimab-for-locally-advanced-cervical-cancer-100525955","NCT06128460","Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.","Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer (IB3, IIA2) Patients","Inclusion Criteria:\n\n* Histologically confirmed cervical squamous cell carcinoma, cervical adenocarcinoma, or cervical adenosquamous carcinoma;\n* According to FIGO2018 staging, patients with locally advanced cervical cancer (IB3, IIA2) who require concurrent radiotherapy and chemotherapy;\n* Patients with radical surgery for cervical cancer;\n* Female patients: 18-70 years old;\n* ECOG physical condition score: 0\\~1 point;\n* Subjects have not received previous immunotherapy;\n* Expected survival ≥6 months;\n* Women of reproductive age should agree to use contraceptives (such as Iuds, contraceptives, or condoms) during the study period and for 6 months after the study ends; Have a negative serum or urine pregnancy test within 7 days prior to study enrollment and must be a non-lactating patient;\n* For adequate organ function as defined in the protocol, test samples must be collected within 7 days prior to initiation of the study therapy\n* Subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.\n\nExclusion Criteria:\n\n* Subjects have histological subtypes other than those permitted by inclusion criteria;\n* Severe hypersensitivity to cepalizumab and\u002For any of its excipients (≥ grade 3);\n* Participate in or have participated in other clinical trials within 4 weeks before enrollment;\n* Have received or will receive inactivated vaccine within 30 days prior to the first study treatment;\n* Received a combination of systemic immune stimulants, colony-stimulating factors, interferon, interleukin, and vaccine within 6 weeks or 5 half-lives (if shorter) prior to initial administration;\n* Have been diagnosed with an immune deficiency or are receiving chronic systemic steroid therapy (doses greater than 10mg daily equivalent of prednisone) or any other form of immunosuppressive therapy within 7 days prior to the first dose;\n* Have an active autoimmune disease in the past 2 years that requires systemic treatment (such as the use of disease-modulating drugs, corticosteroids, or immunosuppressive drugs);\n* Have a history of (non-infectious) pneumonia requiring steroid treatment or have a current (non-infectious) pneumonia;\n* An active infection requiring systematic treatment;\n* Known history of HIV infection;\n* A known history of hepatitis B (defined as HBsAg reactive) or known active hepatitis C virus (defined as detection of HCV RNA\\[qualitative\\]) infection;\n* Known active tuberculosis (TB; Tuberculosis) medical history;\n* Has received allogeneic tissue\u002Fsolid organ transplantation;\n* Suffering from central nervous system metastases such as brain metastases;\n* Patients with uncontrolled chest and abdominal fluid;\n* Patients with mobility disorders such as pathological fractures caused by tumor bone metastasis;\n* Insufficient hematopoietic function of bone marrow;\n* Abnormal liver;\n* Abnormal kidney;\n* Bleeding risk;\n* Cardiovascular and cerebrovascular abnormalities.",{"count":419,"type":21},24,[24],"Locally advanced cervical cancer (stage IB3, IIA2) patients with postoperative risk factors need better treatment. We initiated a clinical study to explore the effectiveness of adjuvant chemoradiotherapy followed by Zimberelimab for these patients.",[56],"2023-11-27",{"date":425,"type":35},"2023-11-30",{"date":427,"type":21},"2023-12-01",{"date":429,"type":21},"2029-12-01",{"name":41,"class":42},{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":11,"sex":16,"minAge":439,"maxAge":271,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":445,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":43},"100434643","laparoscopic-or-abdominal-radical-hysterectomy-for-cervical-cancerstage-ib3iia2-100434643","NCT04939831","Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB3,IIA2)","A Multicenter Noninferior Randomized Controlled Study Comparing the Efficacy of Laparoscopic Versus Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB3,IIA2)","LAUNCH 3","Inclusion Criteria:\n\n1. Clinical diagnosis of squamous carcinoma of the cervix, adenocarcinoma, squamous adenocarcinoma (Stage IB3,IIA2).\n2. Age ≥ 21 years and ≤ 70 years.\n3. Surgery type B and C (refer to Q-M surgical staging)\n4. Normal range of liver and kidney function and blood count (specific details below) Hemoglobin \\> 60g\u002FL Platelets \\> 70\\*109\u002FL Leukocytes \\> 3\\*109\u002FL Creatinine \\\u003C 50mg\u002FdL Transaminase abnormal indicators ≤ 3 Maximum value of transaminases not exceeding 3 times the corresponding normal value.\n5. No history of other malignancies.\n6. Non-pregnancy.\n7. Physical strength classification: Karnofsky score ≥ 60;\n8. Subjects voluntarily joined the study, signed the informed consent form, were compliant and cooperated with the follow-up.\n9. No psychiatric disorders and other serious immune system disorders (e.g. lupus erythematosus, myasthenia gravis, HIV infection, etc.) (Note: Maximum diameter measurement of cervical lesions is based on PET-CT, or CT, or MRI)\n\nExclusion Criteria:\n\n1. Those who are contraindicated for various surgeries and cannot undergo surgery.\n2. Patients who have received pelvic\u002Fabdominal radiotherapy irradiation or neoadjuvant chemotherapy for cervical cancer.\n3. Patients with recurrent cervical cancer\n4. Patients with CT, MRI or PET-CT suggesting suspicious metastasis of pelvic lymph nodes with maximum diameter \\>2cm after further improvement of preoperative examination.","21 Years",{"count":441,"type":21},1104,[79],"The purpose of this study is to confirm whether there is a difference between laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) in patient survival for Cervical Cancer (Stage IB3, IIA2).",[56],[56,446,447],"Abdominal Radical Hysterectomy","Laparoscopic Radical Hysterectomy","2021-11-02",{"date":450,"type":35},"2021-11-10",{"date":452,"type":35},"2021-05-12",{"date":454,"type":21},"2026-06",{"name":41,"class":42},{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":11,"sex":16,"minAge":439,"maxAge":271,"enrollmentInfo":464,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":467,"conditions":468,"keywords":469,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":43},"100433872","laparoscopic-or-abdominal-radical-hysterectomy-for-cervical-cancerstage-ib1ib2iia1-100433872","NCT04929769","Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB1,IB2,IIA1)","A Multicenter Noninferior Randomized Controlled Study Comparing the Efficacy of Laparoscopic Versus Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB1,IB2,IIA1)","LAUNCH 2","Inclusion Criteria:\n\n1. Clinical diagnosis of squamous carcinoma of the cervix, adenocarcinoma, squamous adenocarcinoma (Stage IB1,IB2,IIA1).\n2. Age ≥ 21 years and ≤ 70 years.\n3. Surgery type B and C (refer to Q-M surgical staging)\n4. Normal range of liver and kidney function and blood count (specific details below) Hemoglobin \\> 60g\u002FL Platelets \\> 70\\*109\u002FL Leukocytes \\> 3\\*109\u002FL Creatinine \\\u003C 50mg\u002FdL Transaminase abnormal indicators ≤ 3 Maximum value of transaminases not exceeding 3 times the corresponding normal value.\n5. No history of other malignancies.\n6. Non-pregnancy.\n7. Physical strength classification: Karnofsky score ≥ 60;\n8. Subjects voluntarily joined the study, signed the informed consent form, were compliant and cooperated with the follow-up.\n9. No psychiatric disorders and other serious immune system disorders (e.g. lupus erythematosus, myasthenia gravis, HIV infection, etc.) (Note: Maximum diameter measurement of cervical lesions is based on PET-CT, or CT, or MRI)\n\nExclusion Criteria:\n\n1. Those who are contraindicated for various surgeries and cannot undergo surgery.\n2. Patients who have received pelvic\u002Fabdominal radiotherapy irradiation or neoadjuvant chemotherapy for cervical cancer.\n3. Patients with recurrent cervical cancer\n4. Patients with CT, MRI or PET-CT suggesting suspicious metastasis of pelvic lymph nodes with maximum diameter \\>2cm after further improvement of preoperative examination.",{"count":465,"type":21},780,[79],"The purpose of this study is to confirm whether there is a difference between laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) in patient survival for Cervical Cancer (Stage IB1, IB2, IIA1).",[56],[56,446,447],"2021-10-25",{"date":472,"type":35},"2021-11-01",{"date":474,"type":35},"2021-05-07",{"date":476,"type":21},"2026-09-07",{"name":41,"class":42},""]